Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications... Show more
SNDX saw its Momentum Indicator move above the 0 level on November 06, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for SNDX just turned positive on November 05, 2025. Looking at past instances where SNDX's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
SNDX moved above its 50-day moving average on November 10, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for SNDX moved out of overbought territory on November 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for SNDX crossed bearishly below the 50-day moving average on October 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SNDX broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNDX entered a downward trend on November 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SNDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.642) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (13.055) is also within normal values, averaging (322.723).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of biopharmaceuticals for novel cancer therapies
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CDOYX | 43.43 | 0.27 | +0.63% |
| Columbia Dividend Opportunity Inst3 | |||
| SFLNX | 32.11 | 0.06 | +0.19% |
| Schwab Fundamental US Large Company Idx | |||
| KSDIX | 17.28 | 0.02 | +0.12% |
| Keeley Gabelli Small Cap Dividend I | |||
| MIOIX | 32.76 | N/A | N/A |
| Morgan Stanley Inst International Opp I | |||
| MDODX | 11.41 | -0.02 | -0.17% |
| Morgan Stanley Developing Opportunity R6 | |||
A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To SNDX | 1D Price Change % | ||
|---|---|---|---|---|
| SNDX | 100% | -5.30% | ||
| REPL - SNDX | 51% Loosely correlated | -0.99% | ||
| ACLX - SNDX | 45% Loosely correlated | -0.09% | ||
| VCYT - SNDX | 45% Loosely correlated | -0.84% | ||
| IDYA - SNDX | 43% Loosely correlated | -0.19% | ||
| XENE - SNDX | 43% Loosely correlated | -0.60% | ||
More | ||||